| __timestamp | AstraZeneca PLC | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 46425000 |
| Thursday, January 1, 2015 | 5997000000 | 81491000 |
| Friday, January 1, 2016 | 5890000000 | 94291000 |
| Sunday, January 1, 2017 | 5757000000 | 121827000 |
| Monday, January 1, 2018 | 5932000000 | 160524000 |
| Tuesday, January 1, 2019 | 5958000000 | 200000000 |
| Wednesday, January 1, 2020 | 5991000000 | 275000000 |
| Friday, January 1, 2021 | 9736000000 | 328100000 |
| Saturday, January 1, 2022 | 9762000000 | 463800000 |
| Sunday, January 1, 2023 | 10935000000 | 565000000 |
| Monday, January 1, 2024 | 13583000000 | 731100000 |
Unveiling the hidden dimensions of data
In the ever-evolving world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. AstraZeneca PLC and Neurocrine Biosciences, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, reflecting its robust investment in pioneering treatments. In contrast, Neurocrine Biosciences, Inc. increased its R&D spending by over 1,100%, albeit from a smaller base, highlighting its aggressive push into new therapeutic areas.
AstraZeneca's R&D expenditure consistently exceeded $5 billion annually, peaking at over $10 billion in 2023. Meanwhile, Neurocrine's spending grew from under $50 million in 2014 to over $500 million in 2023. This stark difference underscores the diverse strategies these companies employ to drive innovation and maintain competitive edges in the pharmaceutical industry.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Zoetis Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Analyzing R&D Budgets: GSK plc vs Neurocrine Biosciences, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc. Allocate Funds
Comparing Innovation Spending: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xencor, Inc.
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.